Education
About Us
Working with TipRanks
Follow Us
Newamsterdam Pharma Company N.V. (NAMS)
:NAMS
NAMS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.19 - $27.29
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.05M
Market Cap
$2.57B
Enterprise Value$1.15B
Total Cash (Recent Filing)$771.74M
Total Debt (Recent Filing)$448.00K
Price to Earnings (P/E)―
Beta1.60
Next Earnings
May 07, 2025EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding109,817,810
10 Day Avg. Volume1,254,346
30 Day Avg. Volume1,046,447
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)79.94
Price to Cash Flow (P/CF)-52.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit25.26
Enterprise Value/Ebitda-4.81
Forecast
1Y Price Target
$43.43Price Target Upside85.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
NewAmsterdam Pharma Company News
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessRecent positive data from both Ph.3 BROADWAY (monotherapy) & Ph.3 TANDEM (fixed-dose combination) trials demonstrated obi's robust efficacy in LDL-C reduction with a placebo-like safety profile.
Financial PositionThe company is well-funded with cash of ~$834MM for operations beyond the PREVAIL CVOT readout and potential obi commercial launch.
Strategic DevelopmentsNewAmsterdam (NAMS) delivered a compelling 2025 strategic roadmap that significantly derisks their path to commercialization of lead asset obicetrapib (obi), reinforcing the view that obi could transform the future cardiovascular disease treatment landscape, if approved.
Bears Say
R&D ExpensesPrice target moves to $42 from $46 to reflect model updates with higher than expected R&D in 2025.
Timeline For DataThe next significant data catalyst is not expected until PREVAIL CVOT.
---
Ownership Overview
16.25% Insiders
4.23% Mutual Funds
63.79% Other Institutional Investors
14.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAMS FAQ
What was Newamsterdam Pharma Company N.V.’s price range in the past 12 months?
Newamsterdam Pharma Company N.V. lowest stock price was $15.19 and its highest was $27.29 in the past 12 months.
What is Newamsterdam Pharma Company N.V.’s market cap?
Newamsterdam Pharma Company N.V.’s market cap is $2.57B.
When is Newamsterdam Pharma Company N.V.’s upcoming earnings report date?
Newamsterdam Pharma Company N.V.’s upcoming earnings report date is May 07, 2025 which is in 41 days.
How were Newamsterdam Pharma Company N.V.’s earnings last quarter?
Newamsterdam Pharma Company N.V. released its earnings results on Feb 26, 2025. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.528 by -$0.402.
Is Newamsterdam Pharma Company N.V. overvalued?
According to Wall Street analysts Newamsterdam Pharma Company N.V.’s price is currently Undervalued.
Does Newamsterdam Pharma Company N.V. pay dividends?
Newamsterdam Pharma Company N.V. does not currently pay dividends.
What is Newamsterdam Pharma Company N.V.’s EPS estimate?
Newamsterdam Pharma Company N.V.’s EPS estimate is -0.5.
How many shares outstanding does Newamsterdam Pharma Company N.V. have?
Newamsterdam Pharma Company N.V. has 109,817,810 shares outstanding.
What happened to Newamsterdam Pharma Company N.V.’s price movement after its last earnings report?
Newamsterdam Pharma Company N.V. reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.528. Following the earnings report the stock price went up 10.235%.
Which hedge fund is a major shareholder of Newamsterdam Pharma Company N.V.?
Currently, no hedge funds are holding shares in NAMS
---
NewAmsterdam Pharma Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.43 (85.52% Upside)
$43.43 (85.52% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Company Description
Newamsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
---
NAMS Stock 12 Month Forecast
Average Price Target
$43.43
▲(85.52% Upside)
Technical Analysis
Amarin
―
Madrigal Pharmaceuticals
―
Esperion
―
Viking Therapeutics
―
Akero Therapeutics
―
Best Analysts Covering NAMS
1 Year
1 Year Success Rate
7/7 ratings generated profit
1 Year Average Return
+23.49%
reiterated a buy rating 16 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +23.49% per trade.
---